

## **Nidda Healthcare Holding GmbH Announces Potential Refinancing**

**Bad Vilbel, April 18, 2023.** Nidda Healthcare Holding GmbH (the “Company”), a holding company of STADA Arzneimittel AG, announced today that it intends to enter into discussions with certain investors regarding a potential refinancing on a leverage neutral basis (excluding fees and expenses) of up to €250 million of its existing near-term maturing debt with new debt maturing beyond 2026 (subject to a springing maturity if prior-maturing debt is not repaid). There can be no assurance that the refinancing will occur or, if it does, as to the terms of the refinancing.

In connection with these discussions, the company also disclosed the following recent trading information:

- Net sales were €1,041 million in the three months ended March 31, 2023, an increase of 18% compared to the three months ended March 31, 2022. Net sales performance was driven by strong growth across all three segments and most therapeutic areas and countries, which more than offset forward-buying effects in Russia in March 2022.
- Adjusted Gross Margin was 53.1% in the three months ended March 31, 2023, an increase of 1.9% compared to the three months ended March 31, 2022, driven by successful execution of net price adjustments and cost of goods sold efficiencies, which more than offset the impact of inflation.
- Adjusted EBITDA was €262 million in the three months ended March 31, 2023, an increase of 24% compared to the three months ended March 31, 2022, driven by our enhanced gross margin coupled with prudent, return-on-investment based operating expense incurrence.
- Reported EBITDA was €976 million in the twelve months ended March 31, 2023, an increase of €89 million compared to the year ended December 31, 2022.
- Pro Forma Adjusted EBITDA was €1,001 million in the twelve months ended March 31, 2023, an increase of €66 million compared to the year ended December 31, 2022, despite adjustments trending down to €25 million from €48 million in the prior period.
- The ratio of Pro Forma Net Debt to Pro Forma Adjusted EBITDA was approximately 5.5x as of March 31, 2023.
- The ratio of Pro Forma Net Senior Secured Debt to Pro Forma Adjusted EBITDA was approximately 4.9x as of March 31, 2023.

\*\*\*\*\*

### **No Offer**

*This document is not an offer of securities for sale in the United States. It may also be unlawful to distribute this document in certain jurisdictions. This document is not for distribution in Canada, Japan or Australia. The information in this document does not constitute an offer of securities for sale in Canada, Japan or Australia.*

## **Forward-looking statements**

*This announcement may include projections and other “forward-looking” statements within the meaning of applicable securities laws. Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. You should not place undue reliance on forward-looking statements and the Company does not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise.*

*The preliminary financial results as of and for the three months ended March 31, 2023, and the twelve months ended March 31, 2023, presented above have not been audited or reviewed by the Company’s independent auditors, nor have any procedures been performed by its independent auditors with respect thereto. Such information has been derived from management accounts, is preliminary and is subject to financial closing procedures which have not yet been completed. While the Company believes these preliminary results and estimates to be reasonable, its actual results could vary from these estimates and these differences could be material. As such, you should not place undue reliance on this information and this information may not be indicative of the Company’s performance in the remainder of the financial year or any future period.*